Psilocybin, a classical tryptamine hallucinogen, serves as a model of acute psychosis in humans. Intoxication with this compound induces significant alterations in perception, thought disturbance and emotional processing, effects that mimic psychotic symptoms. The neurochemical basis of its effects is related to the stimulation of serotonin 5-HT 1A a 5-HT 2A/C receptors. Disconnection is one of the core neurobiological features underlying psychosis with altered connectivity of resting state (default mode (DMN)) and executive (EN) and salient (SN) brain networks. Anterior posterior cingulum (ACC and PCC), cuneus and precuneus, orbitofrontal, dorsolateropreforntal (DLPFC), medial prefrontal cortex (mPFC) and insula are the key structures within these networks. Dysfunctional switching between these networks might underlie psychotic symptoms, e.g. hallucinations as misinterpretation of what are our own thoughts and what is perception of external stimuli.
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Spatial components of magnetic mismatch negativity and the cortical thickness of its structural correlates in schizophrenia Jiyoon Jasmine Seol, Kang Ik K Cho, Chun Kee Chung, Minah Kim, Sung Nyun Kim, Jun Soo Kwon, Je-Yeon Yun Seoul National University, Republic of Korea The automatic auditory change detection response observed through the mismatch negativity (MMN) component of eventrelated potentials has been methodically studied in schizophrenia. MMN amplitude attenuation is a consistent finding in this population, and its generators are said to be localized in temporal, contributing to auditory perception and discrimination, and frontal, attention-switching, cortices. Studies of brain structure in schizophrenia have reported abnormalities in several areas, including those that are thought to be involved in the MMN response. However, the potential relationship between MMN and the characteristics of related brain areas is unclear and warrant further exploration. We conducted a magnetoencephalography study of MMN in 16 schizophrenia patients and 18 healthy control subjects. Through source reconstruction, we extracted whole-brain current source density (CSD) strengths using minimum norm estimation, and focused on areas previously reported as potential generators of MMN. We also went on to examine structural MRI data for cortical thickness. In comparison to healthy control subjects, patients with schizophrenia showed significantly decreased CSD strengths in both temporal and frontal areas of interest. The CSD strengths of both temporal and frontal areas showed positive correlations with cortical thickness in the control group. On the other hand, we observed a negative relationship between CSD and thickness in the patient group. Our findings may provide insight on the complex relationship between functional and structural abnormalities observed in schizophrenia.
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Theory of Mind in Clinical high risk as trait marker of conversion to psychosis: review
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Impaired glucose tolerance, symptoms and cognitive deficits in first-episode drug-naïve patients with schizophrenia University of Texas Medical School at Houston, USA Abstract Objective: Schizophrenia patients have a higher prevalence of type 2 diabetes mellitus than the general population, and even first-episode, drug-naive (FEDN) patients with schizophrenia have shown a higher prevalence of impaired glucose tolerance (IGT) than the general population. We aimed to investigate the prevalence of abnormal glucose tolerance after glucose loading, and to examine the relationship between IGT and clinical phenotypes or cognitive deficits in FEND patients with schizophrenia among a Han Chinese population. Method: 175 inpatients meeting DSM-IV schizophrenia criteria were compared with 31 healthy controls on anthropometric measures and fasting plasma levels of glucose, insulin and lipids. They were also compared using a 75-g oral glucose tolerance test (OGTT) and a homeostasis model assessment of insulin resistance (HOMA-IR). Neurocognitive functioning was assessed using the MATRICS Consensus Cognitive Battery (MCCB). Patient psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Results: Among the patients, 24.5% had IGT, compared to none of the healthy controls. Also, the patients had significantly higher levels of fasting glucose and two-hour glucose, and were more insulin resistant as measured with HOMA. Compared to those patients without IGT, the IGT patients were older, had a later age of schizophrenia onset, higher waist or hip circumference and BMI, higher levels of low-density lipoprotein and triglycerides and higher insulin resistance. Furthermore, IGT patients had higher PANSS total and negative symptom subscale scores, but no greater cognitive impairment except on the emotional intelligence index of the MCCB. Conclusions: More IGT occurs in FEDN patients with schizophrenia than controls, and is associated with demographic and anthropometric parameters, as well as with clinical symptoms but minimally with cognitive impairment, suggesting that abnormal glucose metabolism may be associated with clinical symptoms but not with cognitive impairment in schizophrenia during the early phases of the disease.
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Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG Filip Tyls, Tomas Palenicek Michaela Viktorinova, Dominika Prokopcova, Jakub Korcak, Renata Androvicova, Martin Brunovsky, Jiri Horacek National Institute of Mental Health Czech Republic, Topolová 748, 250 67 Klecany, Czech Republic 3 rd Medical Faculty, Charles University, Czech Republic Abstract Objectives: The serotonergic hallucinogen psilocybin, has profound effects on the human mind, which can be characterized by alteration in perception, thinking disorder and strong emotional salience. The character of the altered state of consciousness induced by hallucinogens is hardly predictable; while an important role has the environment in which psilocybin is administered (setting). Methods: Twenty volunteers completed the psilocybin (0.26 mg/ kg, average dose 18.7 mg) session in a double-blind, placebo-controlled arrangement in a comfortable living-room-like setting. This study describes the phenomenology (evaluated objectively by Brief Psychiatric Rating Scale (BPRS) and subjectively by Altered States of Consciousness Scale (ASCS)), physiological parameters and pharmacokinetics of psilocybin intoxication. It also focuses on the relationship between electrophysiological measures of brain activity and phenomenology. Results: The effects of psilocybin peaked in 60 minutes (average blood levels 20 ng/ml) and subsided after 6 hours (average blood levels 4 ng/ml). Psilocybin induced mydriasis (rarely anisocoria), an increase in blood pressure and heart rate compared to placebo. A significant increase of psychopathology was documented by BPRS (subscale thought disorder and hallucinations) and ASCS (subscales visual restructuralization, oceanic boundlessness and to a lesser extent anxious ego dissolution). Psilocybin decreased the EEG spectral power in alpha frequency band, however increased the power of gamma oscillations. The LORETA analysis revealed the source of decreased alpha in midline parietal structures and occipital lobes. The increase in higher frequencies was pronounced in large temporal areas. EEG findings will be correlated with neuropsychiatric scales. Conclusion: We confirmed the safety and beneficial effects of psilocybin administration in a clinical trial under controlled experimental conditions. The decrement of EEG alpha activity was observed mainly in brain structures involved in Default Mode Network, which is thought to represent introspective processes. We hope that these findings will help facilitate future clinical trials using psychedelic substances in patients.
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